Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Payables (2016 - 2026)

Amphastar Pharmaceuticals has reported Payables over the past 13 years, most recently at $32.6 million for Q4 2025.

  • For Q4 2025, Payables fell 79.25% year-over-year to $32.6 million; the TTM value through Dec 2025 reached $32.6 million, down 79.25%, while the annual FY2025 figure was $32.6 million, 79.25% down from the prior year.
  • Payables for Q4 2025 was $32.6 million at Amphastar Pharmaceuticals, down from $190.8 million in the prior quarter.
  • Over five years, Payables peaked at $190.8 million in Q3 2025 and troughed at $18.8 million in Q2 2023.
  • A 5-year average of $67.2 million and a median of $35.3 million in 2024 define the central range for Payables.
  • Biggest five-year swings in Payables: crashed 80.72% in 2023 and later surged 459.86% in 2025.
  • Year by year, Payables stood at $89.5 million in 2021, then crashed by 77.11% to $20.5 million in 2022, then soared by 355.42% to $93.4 million in 2023, then surged by 68.22% to $157.1 million in 2024, then crashed by 79.25% to $32.6 million in 2025.
  • Business Quant data shows Payables for AMPH at $32.6 million in Q4 2025, $190.8 million in Q3 2025, and $166.6 million in Q2 2025.